GONĚC, Tomáš, Hana MICHNOVÁ, Kateřina KLEINEROVÁ, Gabriela BUČKOVÁ, Alois ČÍŽEK and Josef JAMPÍLEK. SYNTHESIS OF NOVEL 2-(PHENYLCARBAMOYL)NAPHTHALENE-1-YL ALKYLCARBAMATES POSSESSING EXCELLENT ANTIMICROBIAL ACTIVITY AGAINST MRSA. In 49th Conference Synthesis and Analysis of Drugs 2021 Hradec Králové. 2021.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name SYNTHESIS OF NOVEL 2-(PHENYLCARBAMOYL)NAPHTHALENE-1-YL ALKYLCARBAMATES POSSESSING EXCELLENT ANTIMICROBIAL ACTIVITY AGAINST MRSA
Name in Czech Syntéza nových 2-(fenylkarbamoyl)naftalen-1-yl alkylkarbamátů s výbornou antimikrobiální aktivitou proti MRSA
Authors GONĚC, Tomáš (203 Czech Republic, guarantor, belonging to the institution), Hana MICHNOVÁ (203 Czech Republic), Kateřina KLEINEROVÁ (203 Czech Republic), Gabriela BUČKOVÁ (703 Slovakia), Alois ČÍŽEK (203 Czech Republic) and Josef JAMPÍLEK (203 Czech Republic).
Edition 49th Conference Synthesis and Analysis of Drugs 2021 Hradec Králové, 2021.
Other information
Original language English
Type of outcome Presentations at conferences
Field of Study 10401 Organic chemistry
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14160/21:00123444
Organization unit Faculty of Pharmacy
Keywords in English synthesis; antimicrobial; MRSA
Tags International impact
Changed by Changed by: PharmDr. Tomáš Goněc, Ph.D., učo 39112. Changed: 22/2/2022 00:00.
Abstract
Recently, we have synthesized novel series of N-phenylhydroxynaphthalene carboxamides possessing promising antimicrobial activities. Introduction of alkylcarbamate moiety lead to enhancement of physical-chemical properties (especially of solubility) and the biological activity was preserved. Series of 13 novel compounds was synthesized and evaluated for antimicrobial activity. Preliminary results showed that all compounds have comparable or much better MIC than standards ciprofloxacin and ampicillin. Best compounds showed MIC in a range of few nM.
Links
MUNI/A/1682/2020, interní kód MUName: Návrh, syntéza a hodnocení derivátů skupin léčiv s inhibiční enzymatickou aktivitou
Investor: Masaryk University
PrintDisplayed: 17/7/2024 09:06